Design Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed Apr 28, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 28, 2026

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	March 31,	December 31,
	2026	2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$12,770	$16,856
Investment securities	210,053	202,989
Prepaid expenses and other current assets	4,226	3,939
Total current assets	227,049	223,784
Property and equipment, net	824	981
Right-of-use asset	2,569	1,438
Total assets	$230,442	$226,203
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,276	$2,312
Accrued expenses and other current liabilities (including related party amounts of $890 as of December 31, 2025)	7,914	10,743
Total current liabilities	10,190	13,055
Operating lease liability	2,198	645
Total liabilities	12,388	13,700
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 62,441,429 and 60,398,051 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	6	6
Additional paid-in capital	532,958	509,100
Accumulated deficit	(314,642)	(297,006)
Accumulated other comprehensive (loss) income	(268)	403
Total stockholders’ equity	218,054	212,503
Total liabilities and stockholders’ equity	$230,442	$226,203

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.